EXPONENTIAL BIOMEDICINE LIMITED

Exponential Biomedicine Limited (EBI) is a cutting‑edge biopharmaceutical company focused on developing a novel class of therapeutics that tackle the duration of postoperative complications in patients undergoing major surgery. Drawing on proprietary polypeptides derived from the human pregnancy hormone, EBI’s lead product targets vascular permeability, surgical stress and microvascular barrier dysfunction to shorten hospital and intensive‑care stays.

The company’s pipeline builds on this core technology, extending into acute systemic inflammation and tissue damage following irradiation treatment. Positive Phase II data have propelled the lead candidate into Phase III trials, underscoring its potential to meet a significant unmet medical need for fast‑acting drugs that improve post‑surgical outcomes. EBI collaborates closely with a distinguished Scientific Advisory Board and external partners, leveraging both internal expertise and strategic alliances to accelerate development and bring its therapies to market.

By marrying innovative peptide science with a clear focus on patient‑centred outcomes, Exponential Biomedicine Limited aims to transform postoperative care for surgeons, hospitals and the patients they serve.